Devicor Medical Products Group LLC, the medical device holding company that bought the breast-care business of Johnson & Johnson’s (NYSE:JNJ) Ethicon Endo-Surgery two weeks ago, drummed up $151.5 million in an equity offering.
News Well
Viking, Boston Scientific extend supply contract
Viking Systems Inc. (OTC:VKNG) extended its supply contract with Boston Scientific Corp. (NYSE:BSX).
The Westborough, Mass.-based company provides the camera, light source and accessories designed specifically for Boston Scientific’s SpyGlass direct visualization system.
FDA panel clears Medtronic’s Amplify spinal implant
Despite its concerns over possible cancer risks associated with Medtronic Inc.’s (NYSE:MDT) Amplify spinal implant, a Food & Drug Administration advisory panel recommended that the federal watchdog agency approve the device.
Halamka’s digest of quality measures for EMR meaningful use
To help all stakeholders who want to better understand the latest healthcare IT regulations:
UPDATE: Covidien closes Somanetics buyout
Covidien plc (NYSE:COV) closed its $25-per-share buyout of Somanetics Corp. (NSDQ:SMTS), saying it can now own about 80 percent of the Troy, Mich.-based pulse oximetry maker.
The Mansfield, Mass.-based medical products conglomerate agreed to pay $250 million for Somanetics in June as part of its ongoing strategy to bolster businesses it thinks are poised to grow and jettison others that aren’t deemed a good fit.
Second proxy advisory firm backs Charles River Labs/WuXi merger
Another proxy advisory firm is backing the proposed, $1.6 billion merger between WuXi PharmaTech (Cayman) Inc. (NYSE:WX) and Charles River Laboratories International Inc. (NYSE:CRL), which has drawn opposition from some of CRL’s top investors.
RiskMetrics Group’s ISS Proxy Advisory Services recommended that WuXi shareholders vote for the acquisition of WuXi.
Hanger Orthopedic extends bottom-line winning streak
Bottom line, Hanger Orthopedic Group (NYSE:HGR) remains perfect at 18-0. The top line, however, is a slightly different story.
For the 18th quarter in a row — a streak extending back to late 2005 — the provider of orthotic and prosthetic patient services has met or beaten consensus profit forecasts. Adjusted second-quarter earnings were $12.2 million, or 37 cents a share, although those results do not include $2.5 million in relocation expenses from moving the company’s headquarters to Austin, Texas, from Bethesda, Md., which would have cut net income to $9.8 million, or 30 cents a share.
Exact Sciences inks biomarkers deal with Belgian firm
Exact Sciences Corp. (NSDQ:EXAS) inked a licensing deal with Belgium-based OncoMethylome Sciences for that company’s DNA methylation biomarkers.
The Madison, Wis.-based company gained exclusive worldwide rights for up to two of OncoMethylome’s biomarkers utilized in its stool-based detection of colorectal cancer, the companies said.
World Heart Corp. wins FDA nod for clinical trial expansion
World Heart Corp. (NSDQ:WHRT) won approval from the Food & Drug Administration to double the size of a clinical trial of its Levacor ventricular assist device.
The Salt Lake City-based company said the federal watchdog OK’d the addition of 10 additional sites to its bridge-to-transplant pivotal trial, taking the total number of eligible sites to 20.
In June, Mass. General Hospital and a pair of hospitals in Kentucky and Florida joined the study.
Report: Medical devices injure 70,000 kids each year
More than 70,000 children are sent to the emergency room each year for injuries and malfunctions from medical devices, according to a study by researchers at the Food & Drug Administration.
Contact lenses account for about a quarter of the problems, with issues such as infection and eye abrasion that can result from wearing the lenses too long.
Hologic has a date with the FDA for its new 3D mammography system
Hologic Inc. (NSDQ:HOLX) announced that its Selenia Dimensions, a 3D digital mammography tomosynthesis system, will be reviewed by the Food & Drug Administration’s Radiological Devices panel.
The review, slated to take place on Sept. 24, is one of the last steps in the device’s pre-market approval application.